Long term outcome of acute myeloid leukemia with t(8;21).
- Author:
Wei LI
1
;
Ying-Chang MI
;
Ying WANG
;
Ming-Wei FU
;
Dong LIN
;
Hui-Jun WANG
;
Xu-Ping LIU
;
Shou-Geng BIAN
;
Jian-Xiang WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Female; Humans; Leukemia, Myeloid, Acute; diagnosis; genetics; mortality; Male; Middle Aged; Prognosis; Survival Rate; Translocation, Genetic; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2009;30(3):186-191
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the influence factors on survival and outcome of acute myeloid leukemia (AML) patients with t(8;21).
METHODSEighty seven AML patients with t(8;21) after long-term follow-up were enrolled in the analysis of clinical feature, immunophenotype, chromosome karyotype, treatment regimen, as well as the overall survival (OS) and relapse-free survival (RFS).
RESULTSThe overall complete remission (CR) rate was 95.3%. CR rate after first course therapy was 69.8%, after first course therapy containing medium dose Ara-C was 86.2%, and after first course of therapy containing standard-dose Ara-C was 60.3%. The median OS duration was 16.4 months, median RFS 11.7 months, 3 year OS rate 42%, 5 year OS rate 39%, 3 year RFS rate 55% and 5 year RFS rate 55%. Male gender chromosome 9q(-) had statistical significance for shorter OS and poor outcome, 2 courses of post-remission therapy with intermediate dose Ara-C, induction therapy with intermediate-dose Ara-C and post-remission with 4 courses consolidation therapy had statistically longer OS and RFS.
CONCLUSIONSex, chromosome karyotype, induction and consolidation therapy were important influence factors on OS and RFS. Application of intermediate dose Ara-C to induction and consolidation therapy leads to a higher CR rate, prolong OS and RFS.
